AbbVie Inc. (BCBA:ABBV)

Market Cap	578.82T
Revenue (ttm)	69.51T
Net Income (ttm)	4.44T
Shares Out	n/a
EPS (ttm)	2,502.76
PE Ratio	130.46
Forward PE	19.59
Dividend	457.95 (1.36%)
Ex-Dividend Date	Jul 15, 2025

Volume	1,143
Average Volume	1,202
Open	36,300
Previous Close	35,680
Day's Range	33,500 - 36,320
52-Week Range	18,325 - 38,540
Beta	n/a
RSI	52.74
Earnings Date	Oct 29, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD